Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms

Grant, 2017, Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United States, 2001-2002 to 2012-2013: results from the National Epidemiologic Survey on Alcohol and Related Conditions., JAMA Psychiatry, 74, 911, 10.1001/jamapsychiatry.2017.2161

Rehm, 2014, Burden of disease associated with alcohol use disorders in the United States., Alcohol Clin Exp Res, 38, 1068, 10.1111/acer.12331

Litten, 2016, Potential medications for the treatment of alcohol use disorder: an evaluation of clinical efficacy and safety., Subst Abus, 37, 286, 10.1080/08897077.2015.1133472

Schuckit, 1998, Clinical relevance of the distinction between alcohol dependence with and without a physiological component., Am J Psychiatry, 155, 733

Caetano, 1998, Prevalence, trends, and incidence of alcohol withdrawal symptoms: analysis of general population and clinical samples., Alcohol Health Res World, 22, 73

Schuckit, 2003, A 5-year prospective evaluation of DSM-IV alcohol dependence with and without a physiological component., Alcohol Clin Exp Res, 27, 818, 10.1097/01.ALC.0000067980.18461.33

Wright, 2007, Impact of lifetime alcohol quit attempts and medicated detoxifications on time to relapse during an index alcohol detoxification., J Addict Med, 1, 15, 10.1097/ADM.0b013e318044ce4f

Bonnet, 1999, Treatment of alcohol withdrawal syndrome with gabapentin., Pharmacopsychiatry, 32, 107, 10.1055/s-2007-979203

Mason, 2009, Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin., Addict Biol, 14, 73, 10.1111/j.1369-1600.2008.00133.x

O’Malley, 2002, Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis., Psychopharmacology (Berl), 160, 19, 10.1007/s002130100919

Drobes, 2004, Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers., Alcohol Clin Exp Res, 28, 1362, 10.1097/01.ALC.0000139704.88862.01

Anton, 2008, Naltrexone for the management of alcohol dependence., N Engl J Med, 359, 715, 10.1056/NEJMct0801733

Ray, 2007, Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study., Arch Gen Psychiatry, 64, 1069, 10.1001/archpsyc.64.9.1069

Schacht, 2017, Predictors of naltrexone response in a randomized trial: reward-related brain activation, OPRM1 genotype, and smoking status., Neuropsychopharmacology, 42, 2640, 10.1038/npp.2017.74

Gass, 2008, Glutamatergic substrates of drug addiction and alcoholism., Biochem Pharmacol, 75, 218, 10.1016/j.bcp.2007.06.039

Koob, 2009, Development of pharmacotherapies for drug addiction: a Rosetta stone approach., Nat Rev Drug Discov, 8, 500, 10.1038/nrd2828

Littleton, 1998, Neurochemical mechanisms underlying alcohol withdrawal., Alcohol Health Res World, 22, 13

Gonzales, 1998, Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens., J Neurosci, 18, 10663, 10.1523/JNEUROSCI.18-24-10663.1998

Schacht, 2019, The dopamine transporter VNTR polymorphism moderates the relationship between acute response to alcohol and future alcohol use disorder symptoms., Addict Biol, 24, 1109, 10.1111/adb.v24.5

Addolorato, 2012, Novel therapeutic strategies for alcohol and drug addiction: focus on GABA, ion channels and transcranial magnetic stimulation., Neuropsychopharmacology, 37, 163, 10.1038/npp.2011.216

Krystal, 2006, Gamma-aminobutyric acid type A receptors and alcoholism: intoxication, dependence, vulnerability, and treatment., Arch Gen Psychiatry, 63, 957, 10.1001/archpsyc.63.9.957

Maneuf, 2006, Alpha2delta and the mechanism of action of gabapentin in the treatment of pain., Semin Cell Dev Biol, 17, 565, 10.1016/j.semcdb.2006.09.003

Zamponi, 2015, The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential., Pharmacol Rev, 67, 821, 10.1124/pr.114.009654

Hendrich, 2008, Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin., Proc Natl Acad Sci U S A, 105, 3628, 10.1073/pnas.0708930105

Sills, 2006, The mechanisms of action of gabapentin and pregabalin., Curr Opin Pharmacol, 6, 108, 10.1016/j.coph.2005.11.003

Yoshizumi, 2012, Gabapentin inhibits ?-amino butyric acid release in the locus coeruleus but not in the spinal dorsal horn after peripheral nerve injury in rats., Anesthesiology, 116, 1347, 10.1097/ALN.0b013e318254e6fd

Suto, 2014, Gabapentin increases extracellular glutamatergic level in the locus coeruleus via astroglial glutamate transporter-dependent mechanisms., Neuropharmacology, 81, 95, 10.1016/j.neuropharm.2014.01.040

Cai, 2012, The impact of gabapentin administration on brain GABA and glutamate concentrations: a 7T 1H-MRS study., Neuropsychopharmacology, 37, 2764, 10.1038/npp.2012.142

Mariani, 2006, A randomized, open-label, controlled trial of gabapentin and phenobarbital in the treatment of alcohol withdrawal., Am J Addict, 15, 76, 10.1080/10550490500419110

Myrick, 2009, A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal., Alcohol Clin Exp Res, 33, 1582, 10.1111/acer.2009.33.issue-9

Furieri, 2007, Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial., J Clin Psychiatry, 68, 1691, 10.4088/JCP.v68n1108

Karam-Hage, 2000, Gabapentin treatment for insomnia associated with alcohol dependence., Am J Psychiatry, 157, 151, 10.1176/ajp.157.1.151

Karam-Hage, 2003, Open pilot study of gabapentin versus trazodone to treat insomnia in alcoholic outpatients., Psychiatry Clin Neurosci, 57, 542, 10.1046/j.1440-1819.2003.01161.x

Anton, 2009, Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms., J Clin Psychopharmacol, 29, 334, 10.1097/JCP.0b013e3181aba6a4

Anton, 2011, Gabapentin combined with naltrexone for the treatment of alcohol dependence., Am J Psychiatry, 168, 709, 10.1176/appi.ajp.2011.10101436

Roberto, 2008, Cellular and behavioral interactions of gabapentin with alcohol dependence., J Neurosci, 28, 5762, 10.1523/JNEUROSCI.0575-08.2008

Mason, 2014, Gabapentin treatment for alcohol dependence: a randomized clinical trial., JAMA Intern Med, 174, 70, 10.1001/jamainternmed.2013.11950

Falk, 2019, Gabapentin enacarbil extended-release for alcohol use disorder: a randomized, double-blind, placebo-controlled, multisite trial assessing efficacy and safety., Alcohol Clin Exp Res, 43, 158, 10.1111/acer.13917

Goldberg, 2001, Cognitive side effects of anticonvulsants., J Clin Psychiatry, 62, 27

Schacht, 2011, Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence., Alcohol Clin Exp Res, 35, 2030, 10.1111/acer.2011.35.issue-11

Bisaga, 2006, The acute effects of gabapentin in combination with alcohol in heavy drinkers., Drug Alcohol Depend, 83, 25, 10.1016/j.drugalcdep.2005.10.008

Myrick, 2007, A double-blind evaluation of gabapentin on alcohol effects and drinking in a clinical laboratory paradigm., Alcohol Clin Exp Res, 31, 221, 10.1111/acer.2007.31.issue-2

Ahmed, 2019, Use of gabapentin in the treatment of substance use and psychiatric disorders: a systematic review., Front Psychiatry, 10, 228, 10.3389/fpsyt.2019.00228

Sullivan, 1989, Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar)., Br J Addict, 84, 1353, 10.1111/add.1989.84.issue-11

Anton, 2006, Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial., JAMA, 295, 2003, 10.1001/jama.295.17.2003

Johnson, 2005, The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field., J Stud Alcohol Suppl, 157, 10.15288/jsas.2005.s15.157

Pittman, 2007, Multidimensionality of the Alcohol Withdrawal Symptom Checklist: a factor analysis of the Alcohol Withdrawal Symptom Checklist and CIWA-Ar., Alcohol Clin Exp Res, 31, 612, 10.1111/j.1530-0277.2007.00345.x

Skinner, 1982, Alcohol dependence syndrome: measurement and validation., J Abnorm Psychol, 91, 199, 10.1037/0021-843X.91.3.199

Anton, 1996, The obsessive compulsive drinking scale: a new method of assessing outcome in alcoholism treatment studies., Arch Gen Psychiatry, 53, 225, 10.1001/archpsyc.1996.01830030047008

Tonigan, 1997, The reliability of Form 90: an instrument for assessing alcohol treatment outcome., J Stud Alcohol, 58, 358, 10.15288/jsa.1997.58.358

Litten, 2010, Alcohol biomarkers in applied settings: recent advances and future research opportunities., Alcohol Clin Exp Res, 34, 955, 10.1111/acer.2010.34.issue-6

Helander, 2010, Toward standardization of carbohydrate-deficient transferrin (CDT) measurements: II. performance of a laboratory network running the HPLC candidate reference measurement procedure and evaluation of a candidate reference material., Clin Chem Lab Med, 48, 1585, 10.1515/CCLM.2010.322

Falk, 2010, Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials., Alcohol Clin Exp Res, 34, 2022, 10.1111/acer.2010.34.issue-12

Anton, 2018, Nicotine-use/smoking is associated with the efficacy of naltrexone in the treatment of alcohol dependence., Alcohol Clin Exp Res, 42, 751, 10.1111/acer.2018.42.issue-4

Laupacis, 1988, An assessment of clinically useful measures of the consequences of treatment., N Engl J Med, 318, 1728, 10.1056/NEJM198806303182605

Anton, 2002, Carbohydrate-deficient transferrin and gamma-glutamyltransferase for the detection and monitoring of alcohol use: results from a multisite study., Alcohol Clin Exp Res, 26, 1215

Helander, 2003, Improved HPLC method for carbohydrate-deficient transferrin in serum., Clin Chem, 49, 1881, 10.1373/clinchem.2003.023341

Kranzler, 2019, A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder., Addiction, 114, 1547, 10.1111/add.v114.9

Leggio, 2008, New developments for the pharmacological treatment of alcohol withdrawal syndrome. a focus on non-benzodiazepine GABAergic medications., Prog Neuropsychopharmacol Biol Psychiatry, 32, 1106, 10.1016/j.pnpbp.2007.09.021

Griffin, 2014, Increased extracellular glutamate in the nucleus accumbens promotes excessive ethanol drinking in ethanol dependent mice., Neuropsychopharmacology, 39, 707, 10.1038/npp.2013.256

Melendez, 2012, Brain region-specific gene expression changes after chronic intermittent ethanol exposure and early withdrawal in C57BL/6J mice., Addict Biol, 17, 351, 10.1111/adb.2012.17.issue-2

Leggio, 2017, Treatment of alcohol use disorder in patients with alcoholic liver disease., Am J Med, 130, 124, 10.1016/j.amjmed.2016.10.004

First, 1997, Structured Clinical Interview for DSM-IV Axis I Disorders—Patient Edition., Version. 2.0

Pettinati, 2004, Medical Management Treatment Manual: A Clinical Research Guide for Medically Trained Clinicians Providing Pharmacotherapy as Part of the Treatment for Alcohol Dependence

American Psychiatric Association, 2000, Handbook of Psychiatric Measures

Center for Drug Evaluation and Research, 2015, Alcoholism: Developing Drugs for Treatment. Guidance for Industry